The partnership between AstraZeneca and the Jenner Institute should jolt our industry and banks

• Coronavirus latest updates
• See all our coronavirus coverage

There was some good news last week. Oxford University’s Jenner Institute announced it was teaming up with AstraZeneca to take a promising prototype of coronavirus vaccine into volume production by the autumn. Of course there are caveats – the institute’s confidence in its vaccine may not be validated by the trials that began last week.

Still it was heartening, after so much tragic incompetence, that a British university and a British company could forge a relationship of such potential national importance.

The piping through which emergency credit must flow is atrophied and weak

Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old.

A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with the former agreeing to aid in the development and large-scale manufacture of the latter’s potential recombinant adenovirus vaccine for the prevention of novel coronavirus infection.

Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year.

AZ has pledged to make the vaccine at cost for the duration of the pandemic

Experts says $20bn needed to vaccinate global population

It is hoped that the drug may prevent COVID-19

As with other companies, US drug giant Pfizer and its German partner BioNTech are moving forward their…

Global coronavirus vaccine makers have been rolling out details about their manufacturing and launch plans—even ahead of any clinical data. Now, Pfizer says it will draw on three sites in the U.S., plus one in Belgium, for the early stages of a launch, provided its BioNTech-partnered shot wins a green light.

Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation have agreed to pay $72.5 million to resolve civil False Claims Act allegations arising from the marketing of the cystic fibrosis drug TOBI.

McKesson Corporation has agreed to pay $18 million to resolve allegations that it improperly set temperature monitors used in shipping vaccines under its contract with the Centers for Disease Control and Prevention (CDC), the Justice Department announced today. McKesson is a pharmaceutical distributor with corporate headquarters in San Francisco

The ongoing COVID-19 pandemic has sickened over 3.25 million people and has killed 233,014 people, according to data from Johns Hopkins University.

J&J agrees a manufacturing partnership with Emergent, as it looks to hit its target of one billion doses.

The company receives approval for MenQuadfi to prevent meningococcal disease.

The WHO and world leaders commit to a fund to accelerate development of vaccines, tests and treatments for COVID-19.

Under the agreement, AZ will develop, manufacture and distribute the vaccine that has already begun Phase I trials.

Catalent announces partnership with J&J to manufacture lead COVID-19 vaccine candidate, plans to hire 300 staff and manufacture 24/7.

The likelihood of an effective vaccine being developed and scaled up in less than 12 months is unrealistic, suggests GlobalData analyst.

Pfizer partners with Valneva to progress Phase II-stage vaccine candidate for Lyme disease.

Moderna announces it has partnered with Lonza with the aim of producing one billion doses annually.

Pfizer and partner BioNTech are right in the middle of one of the most important vaccine trials in the world right now, but that doesn’t mean the Big Pharma is taking its eyes off the inoculation ball elsewhere.

Inovio Pharmaceuticals’ stock has climbed higher and higher over the past month since it said it was working on a speedy COVID-19 vaccine.

Pfizer and BioNTech have begun dosing participants in a U.S. clinical trial of their COVID-19 vaccine candidates. The dose-escalation stage of the trial will enroll up to 360 subjects, initially out of sites in New York and Maryland.

Moderna is finalizing the protocol for a phase 3 trial of its COVID-19 vaccine with a view to starting the study early in the summer. The establishment of the timeline, which follows FDA clearance to run a phase 2 trial, puts Moderna on track to win approval for its mRNA vaccine mRNA-1273 next year.

Scientists work tirelessly to find a coronavirus vaccine. But there are some questions to answer: How soon a viable vaccine would be developed? Would billions of people worldwide be able to to get it?

Experts caution that even promising early results don’t guarantee that vaccines will be widely available anytime soon.

On February 20, the World Bank and the Coalition for Epidemic Preparedness Innovations (CEPI), which funds development of epidemic vaccines, cohosted a global consultation on funding the development and manufacturing of COVID-19 vaccines. We wrote a working paper to guide the consultation, which we coauthored with World Bank and CEPI colleagues. The consultation led to…

On February 20, the World Bank and the Coalition for Epidemic Preparedness Innovations (CEPI), which funds development of epidemic vaccines, cohosted a global consultation on funding the development and manufacturing of COVID-19 vaccines. We wrote a working paper to guide the consultation, which we coauthored with World Bank and CEPI colleagues. The consultation led to…

A government watchdog has found that there is evidence that federal scientist Rick Bright was ousted as head of a health agency for his pushback to a controversial coronavirus drug treatment embraced by President Donald Trump, Bright's lawyers said.

Even as economies start to reopen, Booking Holdings CEO Glenn Fogel said the travel industry will take years to recover to pre-coronavirus levels.

"We will all be supply constrained for quite some time, meaning we won't be able to make as many product as will be required to vaccinate everyone on the planet," CEO Stephane Bancel said on CNBC's "Squawk Box."

"We're here ... doing everything we can to make sure that a vaccine and treatments are available as soon as possible," CEO Robert Kramer said.

"This market does have a tendency to bounce between unbridled optimism and total despair — no middle ground," the "Mad Money" host said.

Pfizer said on Friday it is in talks to shift more of its medicine production to outside contractors as it prepares for large-scale production of an experimental vaccine to prevent Covid-19, should it prove safe and effective.

CNBC's Eamon Javers on a report that Chinese and Iranian hackers have tried to hit U.S. vaccine manufacturers and researchers. CNBC contributor and former Principal Deputy Director of National Intelligence Sue Gordon weighs in on the report.

A team of international experts said that while there was no "magic bullet" for treating Covid-19, successfully identifying a drug that could treat the virus was likely to take less time than rolling out a vaccine.

CNBC's Jim Cramer said Thursday that he has gained confidence in Moderna's potential coronavirus vaccine due to recent comments from Dr. Anthony Fauci.

Moderna has received FDA approval for the company's Covid-19 vaccine to continue into the second phase. CNBC's Meg Tirrell reports.

Experts warn that vaccine timelines look ambitious and argue more thought is needed on manufacturing.

Moderna CEO Stephan Bancel tells "Squawk Box" that he anticipates the supply of Covid-19 vaccines will be 'constrained' at first and that the company will work closely with the U.S. government to distribute the first batches of the vaccine to areas that have the most need.

Donald Trump has asserted with no evidence that the coronavirus pandemic will ‘go away without a vaccine’. Without mentioning specifics, he pointed to other viruses and flus that ‘disappeared’ before vaccines were created. ‘They’ve never shown up again. They die, too. Like everything else, they die,’ Trump said. ‘It’s going to go away. And we’re not going to see it again, hopefully, after a period of time.’

• Global report: Trump says Covid-19 will ‘go away without vaccine’, expects US death toll to top 95,000
  
• Coronavirus US live: Trump fumes as White House staffers test positive and death toll nears 80,000